Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16244795 | 0.81 | CTH (0.39) | CTHALDH1A1RARB | |
| SCHEMBL21449551 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20915371 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL22273360 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20915256 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20915198 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20936451 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20915385 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL20936519 | 0.79 | PLA2G2A (0.40) | ALDH1A1PLA2G2A | |
| SCHEMBL84973 | 0.79 | CTH (0.42) | CTHALDH1A1RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| EP-3212643-B1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-20 | — | — | EP | disclosed |
| EP-3354651-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| US-9850236-B2 | Trifluoromethyl alcohols as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-16 | — | — | US | disclosed |
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| US-8212052-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122336-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | RORC, RORA, RORB | CTH 4638/4885ALDH1A1 59/4885RARB 16/4885 |
| US-20090149521-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | CTH 4406/4885ALDH1A1 2053/4885RARB 2889/4885 |
| US-20170327492-A1 | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | RORA, RORC, RORB | CTH 4655/4885ALDH1A1 50/4885RARB 13/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | CTH 3317/4885ALDH1A1 919/4885RARB 539/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | CTH 3317/4885ALDH1A1 919/4885RARB 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.